Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'TOPOISOMERASE-I INHIBITOR' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 151 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Seiter, K; Liu, DL; Feldman, EJ; Siddiqui, AD; Hoang, A; Baskind, P; Kancherla, R; Ahmed, T
      Intravenous bolus topotecan in patients with myelodysplastic syndrome

      LEUKEMIA & LYMPHOMA
    2. Takagi, T; Saotome, T
      Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma

      LEUKEMIA & LYMPHOMA
    3. Platzer, P; Thalhammer, T; Reznicek, G; Hamilton, G; Zhang, RW; Jager, W
      Metabolism and biliary excretion of the novel anticancer agent 10-hydroxycamptothecin in the isolated perfused rat liver

      INTERNATIONAL JOURNAL OF ONCOLOGY
    4. Oka, M; Fukuda, M; Fukuda, M; Kinoshita, A; Kuba, M; Ichiki, M; Rikimaru, T; Soda, H; Takatani, H; Narasaki, F; Nagashima, S; Nakamura, YI; Hayashi, N; Kohno, S
      Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in unresectable and locally advanced non-small cell lung cancer

      EUROPEAN JOURNAL OF CANCER
    5. Yamamoto, W; Verweij, J; de Bruijn, P; de Jonge, MJA; Takano, H; Nishiyama, M; Kurihara, M; Sparreboom, A
      Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells

      ANTI-CANCER DRUGS
    6. Kehrer, DFS; Soepenberg, O; Loos, WJ; Verweij, J; Sparreboom, A
      Modulation of camptothecin analogs in the treatment of cancer: a review

      ANTI-CANCER DRUGS
    7. Demarquay, D; Huchet, M; Coulomb, H; Lesueur-Ginot, L; Lavergne, O; Kasprzyk, PG; Bailly, C; Camara, J; Bigg, DCH
      The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison

      ANTI-CANCER DRUGS
    8. Clarke-Pearson, DL; Van Le, L; Iveson, T; Whitney, CW; Hanjani, P; Kristensen, G; Malfetano, JH; Beckman, RA; Ross, GA; Lane, SR; DeWitte, MH; Fields, SZ
      Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer

      JOURNAL OF CLINICAL ONCOLOGY
    9. Pagano, L; Mele, L; Voso, MT; Chiusolo, P; Putzulu, R; Mazzotta, S; Leone, G
      The association of topotecan and cytarabine in the treatment of secondary or relapsed acute myeloid leukemia

      HAEMATOLOGICA
    10. Das, B; Madhusudhan, P; Reddy, PV; Anitha, Y
      Natural camptothecins

      INDIAN JOURNAL OF CHEMISTRY SECTION B-ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY
    11. Lee, ST; Jang, JH; Suh, HC; Hahn, JS; Ko, YW; Min, YH
      Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome

      AMERICAN JOURNAL OF HEMATOLOGY
    12. Herrington, JD; Figueroa, JA; Kirstein, MN; Zamboni, WC; Stewart, CF
      Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    13. Rodriguez, M; Rose, PG
      Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer

      GYNECOLOGIC ONCOLOGY
    14. Homesley, HD; Hall, DJ; Martin, DA; Lewandowski, GS; Vaccarello, L; Nahhas, WA; Suggs, CL; Penley, RG
      Dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients

      GYNECOLOGIC ONCOLOGY
    15. Fulzele, DP; Satdive, RK; Pol, BB
      Growth and production of camptothecin by cell suspension cultures of Nothapodytes foetida

      PLANTA MEDICA
    16. Eckardt, JR
      Feasibility of oral topotecan in previously untreated patients with small-cell lung cancer ineligible for standard therapy

      ONCOLOGY
    17. Pujol, JL; von Pawel, J; Tumolo, S; Martoni, A; Hearn, S; Fields, SZ; Ross, G
      Preliminary results of combined therapy with topotecan and carboplatin in advanced non-small-cell lung cancer

      ONCOLOGY
    18. Bojarski, C; Gitter, AH; Bendfeldt, K; Mankertz, J; Schmitz, H; Wagner, S; Fromm, M; Schulzke, JD
      Permeability of human HT-29/B6 colonic epithelium as a function of apoptosis

      JOURNAL OF PHYSIOLOGY-LONDON
    19. Beltinger, C; Debatin, KM
      Murine models for experimental therapy of pediatric solid tumors with poorprognosis

      INTERNATIONAL JOURNAL OF CANCER
    20. Kawabata, S; Oka, M; Shiozawa, K; Tsukamoto, K; Nakatomi, K; Soda, H; Fukuda, M; Ikegami, Y; Sugahara, K; Yamada, Y; Kamihira, S; Doyle, LA; Ross, DD; Kohno, S
      Breast cancer resistance protein directly confers SN-38 resistance of lungcancer cells

      BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    21. Loos, WJ; Kehrer, D; Brouwer, E; Verweij, J; de Bruijn, P; Hamilton, M; Gill, S; Nooter, K; Stoter, G; Sparreboom, A
      Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography

      JOURNAL OF CHROMATOGRAPHY B
    22. Hudson, AT
      Patent focus on antiparasitic agents: May-October 1999

      EXPERT OPINION ON THERAPEUTIC PATENTS
    23. Dejosez, M; Ramp, U; Mahotka, C; Krieg, A; Walczak, H; Gabbert, HE; Gerharz, CD
      Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan

      CELL DEATH AND DIFFERENTIATION
    24. Boucaud, M; Pinguet, F; Poujol, S; Astre, C; Bressolle, F
      Sensitive high performance liquid chromatographic fluorescence determination of topotecan in human plasma and parotid saliva

      JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES
    25. Emerson, DL; Bendele, R; Brown, E; Chiang, SM; Desjardins, JP; Dihel, LC; Gill, SC; Hamilton, M; LeRay, JD; Moon-McDermott, L; Moynihan, K; Richardson, FC; Tomkinson, B; Luzzio, MJ; Baccanari, D
      Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: A low-clearance liposomal formulation of lurtotecan

      CLINICAL CANCER RESEARCH
    26. Gelderblom, H; Loos, WJ; Verweij, J; de Jonge, MJA; Sparreboom, A
      Topotecan lacks third space sequestration

      CLINICAL CANCER RESEARCH
    27. Malik, IA
      An open label evaluation of topotecan in patients with relapsed or refractory epithelial ovarian cancer - single institution experience in a developing country

      INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
    28. Cortes, J; Estey, E; Beran, M; O'Brien, S; Giles, F; Koller, C; Keating, M; Kantarjian, H
      Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia

      LEUKEMIA & LYMPHOMA
    29. Jonsson, E; Dhar, S; Jonsson, B; Nygren, P; Graf, W; Larsson, R
      Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines

      EUROPEAN JOURNAL OF CANCER
    30. De Cesare, M; Zunino, F; Pace, S; Pisano, C; Pratesi, G
      Efficacy and toxicity profile of oral topotecan in a panel of human tumourxenografts

      EUROPEAN JOURNAL OF CANCER
    31. Schellens, JHM; Malingre, MM; Kruijtzer, CMF; Bardelmeijer, HA; van Tellingen, O; Schinkel, AH; Beijnen, JH
      Modulation of oral bioavailability of anticancer drugs: from mouse to man

      EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
    32. Beran, M
      Intensive chemotherapy for patients with high-risk myelodysplastic syndrome

      INTERNATIONAL JOURNAL OF HEMATOLOGY
    33. Adams, DJ; Dewhirst, MW; Flowers, JL; Gamcsik, MP; Colvin, OM; Manikumar, G; Wani, MC; Wall, ME
      Camptothecin analogues with enhanced antitumor activity at acidic pH

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    34. Mans, DRA; Di Leone, L; Caldas, APF; Maino, M; Almeida, L; Cancela, AS; Grivicich, I; da Rocha, AB; Schwartsmann, G
      Cellular and clinical pharmacokinetic/pharmacodynamic basis for lack of efficacy of 21-day continuous topotecan in patients with untreated advanced adenocarcinoma of the pancreas

      TUMORI
    35. Asbury, RF; Lipsitz, S; Graham, D; Falkson, CI; Baez, L; Benson, AB
      Treatment of squamous cell esophageal cancer with topotecan - An Eastern Cooperative Oncology Group study (E2293)

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    36. Lee, JH; Ham, YA; Choi, SH; Im, EO; Jung, JH; Im, KS; Kim, DK; Xu, Y; Wang, MW; Kim, ND
      Activity of crude extract of Rubus crataegifolius roots as a potent apoptosis inducer and DNA topoisomesase I inhibitor

      ARCHIVES OF PHARMACAL RESEARCH
    37. Hoelzer, D; Gokbuget, N
      New approaches to acute lymphoblastic leukemia in adults: Where do we go?

      SEMINARS IN ONCOLOGY
    38. Sugiyama, T; Yakushiji, M; Noda, K; Ikeda, M; Kudoh, R; Yajima, A; Tomoda, Y; Terashima, Y; Takeuchi, S; Hiura, M; Saji, F; Takahashi, T; Umesaki, N; Sato, S; Hatae, M; Ohashi, Y
      Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer

      ONCOLOGY
    39. Van Hattum, AH; Pinedo, HM; Schluper, HMM; Hausheer, FH; Boven, E
      New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer

      INTERNATIONAL JOURNAL OF CANCER
    40. Lotz, JP; Lhomme, C; Pautier, P; Couteau, C; Gligorov, J; Alexandre, J; Selle, F; Izrael, V; Maraninchi, D; Viens, P
      High-dose chemotherapy in ovarian adenocarcinoma

      BULLETIN DU CANCER
    41. Tsai, TH; Chen, YF; Chou, CJ; Chen, CF
      Measurement and pharmacokinetics of unbound 20(S)-camptothecin in rat blood and brain by microdialysis coupled to microbore liquid chromatography with fluorescence detection

      JOURNAL OF CHROMATOGRAPHY A
    42. Gerrits, CJH; Schellens, JHM; Burris, H; Eckardt, JR; Planting, AST; van der Burg, MEL; Rodriguez, GI; Loos, WJ; van Beurden, V; Hudson, I; Von Hoff, DD; Verweij, J
      A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (hycamtin)

      CLINICAL CANCER RESEARCH
    43. Matsui, SI; Endo, W; Wrzosek, C; Haridas, K; Seetharamulu, P; Hausheer, FH; Rustum, YM
      Characterisation of a synergistic interaction between a thymidylate synthase inhibitor, ZD1694, and a novel lipophilic topoisomerase I inhibitor karenitecin, BNP1100: Mechanisms and clinical implications

      EUROPEAN JOURNAL OF CANCER
    44. Lee, DS; Lee, SH; Kwon, GS; Lee, HK; Woo, JH; Kim, JG; Hong, SD
      Inhibition of DNA topoisomerase I by dihydrotanshinone I, components of a medicinal herb Salvia miltiorrhiza bunge

      BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY
    45. Beran, M; Estey, E; O'Brien, S; Cortes, J; Koller, CA; Giles, FJ; Kornblau, S; Andreeff, M; Vey, N; Pierce, SR; Hayes, K; Wong, GC; Keating, M; Kantarjian, H
      Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia

      JOURNAL OF CLINICAL ONCOLOGY
    46. Zamboni, WC; Bowman, LC; Tan, M; Santana, VM; Houghton, PJ; Meyer, WH; Pratt, CB; Heideman, RL; Gajjar, AJ; Pappo, AS; Stewart, CF
      Interpatient variability in bioavailability of the intravenous formulationof topotecan given orally to children with recurrent solid tumors

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    47. Del Tacca, M; Di Paolo, A; Danesi, R
      Clinical and preclinical pharmacology of Topotecan

      TUMORI
    48. Vey, N; Kantarjian, H; Beran, M; O'Brien, S; Cortes, J; Koller, C; Estey, E
      Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study

      INVESTIGATIONAL NEW DRUGS
    49. Rosoff, PM; Bayliff, S
      Successful clinical response to irinotecan in desmoplastic round blue celltumor

      MEDICAL AND PEDIATRIC ONCOLOGY
    50. Beran, M; Kantarjian, H
      Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia

      SEMINARS IN HEMATOLOGY
    51. Burris, HA
      The evolving role of oral topotecan

      SEMINARS IN HEMATOLOGY
    52. Yoon, Y; Kim, YO; Lim, NY; Jeon, WK; Sung, HJ
      Shikonin, an ingredient of Lithospermum erythrorhizon induced apoptosis inHL60 human premyelocytic leukemia cell line

      PLANTA MEDICA
    53. Ormrod, D; Spencer, CM
      Topotecan - A review of its efficacy in small cell lung cancer

      DRUGS
    54. de Jonge, MJA; Verweij, J; Loos, WJ; Dallaire, BK; Sparreboom, A
      Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    55. Herben, VMM; Rosing, H; Huinink, WWT; van Zomeren, DM; Batchelor, D; Doyle, E; Beusenberg, FD; Beijnen, JH; Schellens, JHM
      Oral topotecan: bioavailability and effect of food co-administration

      BRITISH JOURNAL OF CANCER
    56. CHOLLET DF; GOUMAZ L; RENARD A; MONTAY G; VERNILLET L; ARNERA V; MAZZO DJ
      SIMULTANEOUS DETERMINATION OF THE LACTONE AND CARBOXYLATE FORMS OF THE CAMPTOTHECIN DERIVATIVE CPT-11 AND ITS METABOLITE SN-38 IN PLASMA BYHIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY

      Journal of chromatography B. Biomedical sciences and applications
    57. Beran, M; Estey, E; O'Brien, SM; Giles, FJ; Koller, CA; Kornblau, S; Keating, M; Kantarjian, HM
      Results of topotecan single-agent therapy in patients with myelodysplasticsyndromes and chronic myelomonocytic leukemia

      LEUKEMIA & LYMPHOMA
    58. SUKHANOVA A; GROKHOVSKY S; ZHUZE A; ROPER D; BRONSTEIN I
      HUMAN DNA-TOPOISOMERASE-I ACTIVITY IS AFFECTED BY BIS-NETROPSINS BINDING TO DNA MINOR-GROOVE

      Biochemistry and molecular biology international
    59. ROSING H; VANZOMEREN DM; DOYLE E; BULT A; BEIJNEN JH
      O-GLUCURONIDATION, A NEWLY IDENTIFIED METABOLIC PATHWAY FOR TOPOTECANAND N-DESMETHYL TOPOTECAN

      Anti-cancer drugs
    60. JANSS AJ; CNAAN A; ZHAO HQ; SHPILSKY A; LEVOW C; SUTTON L; PHILLIPS PC
      SYNERGISTIC CYTOTOXICITY OF TOPOISOMERASE-I INHIBITORS WITH ALKYLATING-AGENTS AND ETOPOSIDE IN HUMAN BRAIN-TUMOR CELL-LINES

      Anti-cancer drugs
    61. IZBICKA E; LAWRENCE R; RAYMOND E; ECKHARDT G; FAIRCLOTH G; JIMENO J; CLARK G; VONHOFF DD
      IN-VITRO ANTITUMOR-ACTIVITY OF THE NOVEL MARINE AGENT, ECTEINASCIDIN-743 (ET-743, NSC-648766) AGAINST HUMAN TUMORS EXPLANTED FROM PATIENTS

      Annals of oncology
    62. HOUGHTON PJ; STEWART CF; THOMPSON J; SANTANA VM; FURMAN WL; FRIEDMAN HS
      PRECLINICAL AND CLINICAL-RESULTS WITH IRINOTECAN - EXTENDING PRINCIPLES LEARNED IN MODEL SYSTEMS TO CLINICAL-TRIALS DESIGN

      Oncology
    63. ROSEN LS
      IRINOTECAN IN LYMPHOMA, LEUKEMIA, AND BREAST, PANCREATIC, OVARIAN, AND SMALL-CELL LUNG CANCERS

      Oncology
    64. KRAUT EH; CROWLEY JJ; WADE JL; LAUFMAN LR; ALSINA M; TAYLOR SA; SALMON SE
      EVALUATION OF TOPOTECAN IN RESISTANT AND RELAPSING MULTIPLE-MYELOMA -A SOUTHWEST-ONCOLOGY-GROUP STUDY

      Journal of clinical oncology
    65. Luck, HJ; Scholz, U; Petry, KU; Bohmer, G; Kuhnle, H
      Importance of topotecan in the therapy of ovarian carcinoma, today and tomorrow

      ONKOLOGIE
    66. Gatzemeier, U
      Hycamtin in the therapy of non-small-cell lung cancer

      ONKOLOGIE
    67. Stewart, CF; Gajjar, AJ; Heideman, RL; Houghton, PJ
      Penetration of topotecan into cerebrospinal fluid after intravenous injection

      ONKOLOGIE
    68. Weihrauch, MR; Tesch, H
      Topotecan in haematologic malignancies

      ONKOLOGIE
    69. IYER L; RATAIN MJ
      CLINICAL-PHARMACOLOGY OF CAMPTOTHECINS

      Cancer chemotherapy and pharmacology
    70. CHOI SH; TSUCHIDA Y; YANG HW
      ORAL VERSUS INTRAPERITONEAL ADMINISTRATION OF IRINOTECAN IN THE TREATMENT OF HUMAN NEUROBLASTOMA IN NUDE-MICE

      Cancer letters
    71. CAMPISI C; ZAPPALA A; TERENZI S; RAVAIOLI M
      ADVANCED OVARIAN-CANCER - STATE-OF-THE-ART AND FUTURE OUTLOOK

      Tumori
    72. Lee, HK; Lee, DS; Lim, J; Kim, JS; Im, KS; Jung, JH
      Topoisomerase I inhibitors from the Streptomyces sp. strain KM86-9B isolated from a marine sponge

      ARCHIVES OF PHARMACAL RESEARCH
    73. TAKIMOTO CH; WRIGHT J; ARBUCK SG
      CLINICAL-APPLICATIONS OF THE CAMPTOTHECINS

      Biochimica et biophysica acta, N. Gene structure and expression
    74. CHESON BD
      STANDARD AND LOW-DOSE CHEMOTHERAPY FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES

      Leukemia research
    75. SIU LL; ROWINSKY EK
      A RISK-BENEFIT ASSESSMENT OF IRINOTECAN IN SOLID TUMORS

      Drug safety
    76. SEITER K
      INDUCTION OF APOPTOSIS BY TOPOTECAN - IMPLICATIONS FOR THE TREATMENT OF LEUKEMIA

      Seminars in hematology
    77. BERAN M; KANTARJIAN H
      TOPOTECAN IN THE TREATMENT OF HEMATOLOGIC MALIGNANCIES

      Seminars in hematology
    78. WINTER S; WELLER M
      POTENTIATION OF CD95L-INDUCED APOPTOSIS OF HUMAN-MALIGNANT GLIOMA-CELLS BY TOPOTECAN INVOLVES INHIBITION OF RNA-SYNTHESIS BUT NOT CHANGES IN CD95 OR CD95L PROTEIN EXPRESSION

      The Journal of pharmacology and experimental therapeutics
    79. MOREAU P; ANIZON F; SANCELME M; PRUDHOMME M; BAILLY C; CARRASCO C; OLLIER M; SEVERE D; RIOU JF; FABBRO D; MEYER T; AUBERTIN AM
      SYNTHESES AND BIOLOGICAL EVALUATION OF INDOLOCARBAZOLES, ANALOGS OF REBECCAMYCIN, MODIFIED AT THE IMIDE HETEROCYCLE

      Journal of medicinal chemistry
    80. IYER L; KING CD; WHITINGTON PF; GREEN MD; ROY SK; TEPHLY TR; COFFMAN BL; RATAIN MJ
      GENETIC PREDISPOSITION TO THE METABOLISM OF IRINOTECAN (CPT-11) - ROLE OF URIDINE-DIPHOSPHATE GLUCURONOSYLTRANSFERASE ISOFORM 1A1 IN THE GLUCURONIDATION OF ITS ACTIVE METABOLITE (SN-38) IN HUMAN LIVER-MICROSOMES

      The Journal of clinical investigation
    81. Dittrich, C
      Topotecan - A new approach in the treatment of ovarian cancer

      GEBURTSHILFE UND FRAUENHEILKUNDE
    82. BROGDEN RN; WISEMAN LR
      TOPOTECAN - A REVIEW OF ITS POTENTIAL IN ADVANCED OVARIAN-CANCER

      Drugs
    83. Boige, V; Raymond, E; Armand, JP
      Irinotecan: drug schedule, research of combinations, and phase I experiences

      BULLETIN DU CANCER
    84. PAZARES L; KUNKA R; DEMARIA D; CASSIDY J; ALDEN M; BERANEK P; KAYE S; LITTLEFIELD D; REILLY D; DEPEE S; WISSEL P; TWELVES C; ODWYER P
      A PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF THE NEW TOPOISOMERASEINHIBITOR GI147211 GIVEN AS A 72-H CONTINUOUS-INFUSION

      British Journal of Cancer
    85. THOMPSON J; ZAMBONI WC; CHESHIRE PJ; LUTZ L; LUO XL; LI YL; HOUGHTON JA; STEWART CF; HOUGHTON PJ
      EFFICACY OF SYSTEMIC ADMINISTRATION OF IRINOTECAN AGAINST NEUROBLASTOMA XENOGRAFTS

      Clinical cancer research
    86. IKEGAMI R; RIVERABENNETTS AK; BROOKER DL; YAGER TD
      EFFECT OF INHIBITORS OF DNA-REPLICATION ON EARLY ZEBRAFISH EMBRYOS - EVIDENCE FOR COORDINATE ACTIVATION OF MULTIPLE INTRINSIC CELL-CYCLE CHECKPOINTS AT THE MID-BLASTULA TRANSITION

      Zygote
    87. LOPEZMEYER M; NESSLER CL
      TRYPTOPHAN DECARBOXYLASE IS ENCODED BY 2 AUTONOMOUSLY REGULATED GENESIN CAMPTOTHECA-ACUMINATA WHICH ARE DIFFERENTIALLY EXPRESSED DURING DEVELOPMENT AND STRESS

      Plant journal
    88. THOMPSON J; ZAMBONI WC; CHESHIRE PJ; RICHMOND L; LUO XL; HOUGHTON JA; STEWART CF; HOUGHTON PJ
      EFFICACY OF ORAL IRINOTECAN AGAINST NEUROBLASTOMA XENOGRAFTS

      Anti-cancer drugs
    89. FUKUOKA K; ADACHI J; NISHIO K; ARIOKA H; KUROKAWA H; FUKUMOTO H; ISHIDA T; NOMOTO T; YOKOTE H; TOMONARI A; NARITA N; YOKOTA J; SAIJO N
      P16(INK4) EXPRESSION IS ASSOCIATED WITH THE INCREASED SENSITIVITY OF HUMAN NONSMALL CELL LUNG-CANCER CELLS TO DNA TOPOISOMERASE-I INHIBITORS

      Japanese journal of cancer research
    90. KANTARJIAN HM; OBRIEN SM; KEATING M; BERAN M; ESTEY E; GIRALT S; KORNBLAU S; RIOS MB; DEVOS D; TALPAZ M
      RESULTS OF DECITABINE THERAPY IN THE ACCELERATED AND BLASTIC PHASES OF CHRONIC MYELOGENOUS LEUKEMIA

      Leukemia
    91. HUININK WTB; GORE M; CARMICHAEL J; GORDON A; MALFETANO J; HUDSON I; BROOM C; SCARABELLI C; DAVIDSON N; SPANCZYNSKI M; BOLIS G; MALMSTROM H; COLEMAN R; FIELDS SC; HERON JF
      TOPOTECAN VERSUS PACLITAXEL FOR THE TREATMENT OF RECURRENT EPITHELIALOVARIAN-CANCER

      Journal of clinical oncology
    92. TAKIMOTO CH; DAHUT W; MARINO MT; NAKASHIMA H; LIANG MD; HAROLD N; LIEBERMAN R; ARBUCK SG; BAND RA; CHEN AP; HAMILTON JM; CANTILENA LR; ALLEGRA CJ; GREM JL
      PHARMACODYNAMICS AND PHARMACOKINETICS OF A 72-HOUR INFUSION OF 9-AMINOCAMPTOTHECIN IN ADULT CANCER-PATIENTS

      Journal of clinical oncology
    93. DAVIES BE; MINTHORN EA; DENNIS MJ; ROSING H; BEIJNEN JH
      THE PHARMACOKINETICS OF TOPOTECAN AND ITS CARBOXYLATE FORM FOLLOWING SEPARATE INTRAVENOUS ADMINISTRATION TO THE DOG

      Pharmaceutical research
    94. ROSING H; HERBEN VMM; VANGORTELVANZOMEREN DM; HOP E; VANDENBOSCH JJK; HUININK WWTB; BEIJNEN JH
      ISOLATION AND STRUCTURAL CONFIRMATION OF N-DESMETHYL TOPOTECAN, A METABOLITE OF TOPOTECAN

      Cancer chemotherapy and pharmacology
    95. ERICKSONMILLER CL; MAY RD; TOMASZEWSKI J; OSBORN B; MURPHY MJ; PAGE JG; PARCHMENT RE
      DIFFERENTIAL TOXICITY OF CAMPTOTHECIN, TOPOTECAN AND 9-AMINOCAMPTOTHECIN TO HUMAN, CANINE, AND MURINE MYELOID PROGENITORS (CFU-GM) IN-VITRO

      Cancer chemotherapy and pharmacology
    96. COGNETTI F
      TOPOTECAN, A NEW DRUG FOR THE TREATMENT O F OVARIAN-CANCER AND SMALL-CELL LUNG-CANCER - SATELLITE SYMPOSIUM OF OCTOBER 4, 1997 - 15TH NATIONAL MEETING ON EXPERIMENTAL AND CLINICAL ONCOLOGY - CHIA-DOMUS-DE-MARIA (CAGLIARI), OCTOBER 4-7, 1997 - INTRODUCTION

      Tumori
    97. SCARFONE G; VILLA A; MORANA S
      TOPOTECAN, A NEW DRUG FOR THE TREATMENT O F EPITHELIAL OVARIAN-CANCER

      Tumori
    98. MALDONADOMENDOZA IE; VINCENT RM; NESSLER CL
      MOLECULAR CHARACTERIZATION OF 3 DIFFERENTIALLY EXPRESSED MEMBERS OF THE CAMPTOTHECA-ACUMINATA 3-HYDROXY-3-METHYLGLUTARYL COA-REDUCTASE (HMGR) GENE FAMILY

      Plant molecular biology
    99. VINCENT RM; LOPEZMEYER M; MCKNIGHT TD; NESSLER CL
      SUSTAINED HARVEST OF CAMPTOTHECIN FROM THE LEAVES OF CAMPTOTHECA-ACUMINATA

      Journal of natural products
    100. KUEFER MU; MOINUDDIN M; HEIDEMAN RL; LUSTIG RH; ROSE SR; BURSTEIN S; VANMIDDLESWORTH L; FLEMING I; JENKINS JJ; SHEARER PD
      PAPILLARY THYROID-CARCINOMA - DEMOGRAPHICS, TREATMENT, AND OUTCOME IN11 PEDIATRIC-PATIENTS TREATED AT A SINGLE INSTITUTION

      Medical and pediatric oncology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 16/01/21 alle ore 11:13:42